Tag

OTC & Consumer Healthcare

1 article

Marksans Pharma Q4FY26 PAT Up 64% YoY

Marksans Pharma reported Q4FY26 PAT of ₹149 crore, up 64.3% YoY, with total income at ₹891 crore. FY26 consolidated revenue reached ₹3,034 crore, a record high, with EBITDA at ₹601 crore and PAT of ₹4